Reto Ritschard

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study

Christoph Mamot, Reto Ritschard, Andreas Wicki et al. · The Lancet Oncology · 2012 · 238 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

Chiara Tarantelli, Eugenio Gaudio, Alberto J. Arribas et al. · Clinical Cancer Research · 2017 · 118 citations

Medicine, Oncology, Pharmacology +13

Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth

Andreas Wicki, Christoph Rochlitz, Annette Orleth et al. · Clinical Cancer Research · 2011 · 91 citations

Medicine, Oncology, Pharmacology +17

EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells

Christoph Mamot, Reto Ritschard, Willy Küng et al. · Journal of drug targeting · 2006 · 68 citations

Pharmacy, Molecular Pharmaceutics, Oncology +17

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Andreas Wicki, Nicholas F. Brown, Alexandros Xyrafas et al. · European Journal of Cancer · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacology +11